This is a contrast between Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) and Molecular Templates Inc. (NASDAQ:MTEM) based on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Diffusion Pharmaceuticals Inc.||N/A||0.00||19.60M||-0.45||0.00|
|Molecular Templates Inc.||9.42M||18.17||30.57M||-1.13||0.00|
Table 1 showcases the gross revenue, earnings per share and valuation of Diffusion Pharmaceuticals Inc. and Molecular Templates Inc.
Table 2 provides the net margins, return on assets and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Diffusion Pharmaceuticals Inc.||0.00%||-79.1%||-69.4%|
|Molecular Templates Inc.||-324.52%||-38.6%||-29.9%|
Risk and Volatility
Diffusion Pharmaceuticals Inc. is 231.00% more volatile than Standard and Poor’s 500 because the company has a beta of -1.31. Molecular Templates Inc.’s 3.15 beta is the reason why it is 215.00% more volatile than Standard and Poor’s 500.
Diffusion Pharmaceuticals Inc.’s Current Ratio is 12.2 while its Quick Ratio is 12.2. On the competitive side is, Molecular Templates Inc. which has a 2.8 Current Ratio and a 2.8 Quick Ratio. Diffusion Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Molecular Templates Inc.
Institutional and Insider Ownership
Roughly 10.7% of Diffusion Pharmaceuticals Inc. shares are held by institutional investors while 70.8% of Molecular Templates Inc. are owned by institutional investors. Insiders held roughly 3.37% of Diffusion Pharmaceuticals Inc.’s shares. Comparatively, Molecular Templates Inc. has 0.7% of it’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Diffusion Pharmaceuticals Inc.||-28.54%||-48.11%||-51.34%||-64.27%||-85.5%||-83.04%|
|Molecular Templates Inc.||-15.73%||-15.07%||-3.98%||-27.3%||-38.53%||-56.69%|
For the past year Molecular Templates Inc. has weaker performance than Diffusion Pharmaceuticals Inc.
Molecular Templates Inc. beats Diffusion Pharmaceuticals Inc. on 5 of the 9 factors.
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. Its lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM. Diffusion Pharmaceuticals Inc. is headquartered in Charlottesville, Virginia.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin’s lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.